Title : GHB-Advisory.pdf

-----------------------------------------------
ADVISORY
Substance Abuse Treatment

November 2002
Volume 2
Issue 1
Breaking News for the Treatment Field

GHB: A Club Drug To Watch

What is GHB?
Gamma hydroxybutyrate (GHB) is one of a group of
club drugs that often are abused by people who attend
a variety of all-night parties sometimes called raves.1
In addition to GHB, the five drugs commonly identified
as club drugs are lysergic acid diethylamide (LSD),
ketamine, methamphetamine, methylenedioxymetham-
phetamine (MDMA, or ecstasy), and rohypnol 
(flunitrazepam).2
GHB is a synthetically produced central nervous system
depressant. On the street, it is usually sold as a liquid
by the dose (a capful from a bottle or drops). In some
cities, GHB is put into water guns, and users buy it by
the squirt. In other instances, candy, such as a lollipop,
is dipped in GHB and sold.3 In liquid form, GHB is
colorless and odorless and has a salty or soapy taste.4
GHB is also sold in powder or capsule form. It is
made of lye or drain cleaner mixed with GBL, a 
chemical cousin of GHB and an industrial solvent
often used to strip floors. GBL itself is often abused
and produces the same effects as GHB. GBL and
another chemical cousin, 1,4 butanediol (1,4 BD), 
convert to GHB in the body. Recipes for GHB can 
easily be found on the Internet. Some GHB users brew
the drug in bathtubs at home.5

Who uses GHB?
The majority of GHB users are young adults. Many of
these users do not realize that GHB affects each person
differently or that differences in the purity and strength
of the dose can mean the difference between life and
death. Misinformation on the Internet, a medium 
widely used by young adults, may also contribute to
Treatment Guidelines for 
GHB Withdrawal

Many clients who use GHB are not dependent on it and
therefore can be educated about its risks and referred for
outpatient therapy. However, clients with a history of 
frequent dosing may experience withdrawal symptoms
and require supervised medical detoxification. In these
situations, providers should note the following:
 GHB withdrawal and detoxification require close
medical supervision. Most clients require
hospitalization ranging from 7 to 14 days.
 Most people who become dependent on GHB find the
withdrawal symptoms unbearable and may try to self-
medicate or self-detoxify with other drugs, including
benzodiazepines, or alcohol. Using other substances
in this way appears to contribute to withdrawal
severity and may lead to respiratory depression,
coma, and death.
 Benzodiazepines can help ease some of the symptoms
of GHB withdrawal, particularly psychotic agitation, if
given in appropriate (and medically supervised) doses.
 Other medications (e.g., barbiturates, anticonvulsants,
and antihypertensives) may be required to effectively
manage GHB withdrawal and detoxification. 
 Another result of GHB withdrawal is amnesia or
memory loss, which greatly complicates a clients
treatment at every stage and may contribute to a
revolving door of treatment episodes and relapse
when the patient has little awareness of the
consequences of his or her GHB addiction.*
Therefore, ongoing client education is critical.
 Although clinicians have gained some insight into
GHB dependence and withdrawal, research on
treatment is an important area to be further
developed. n

*Miotto, K., and Roth, B. GHB Withdrawal Syndrome.
Austin: Texas Commission on Alcohol and Drug Abuse.

continued on reverse...

-----------------------------------------------
November 2002, Volume 2, Issue 1
ADVISORY
Substance Abuse Treatment

the problem. According to a report titled Drugs and the
Internet, by the National Drug Intelligence Center, GHB
is described on many Web sites as a relatively benign
drug.6 Addiction and the possibilities of overdose and
death generally are downplayed. The use of GHB as a
date-rape drug is often dismissed as media hype. 
GHB use is most common among white, middle-class
males between ages 13 and 30. GHB users are likely to use
it with other drugs, particularly ecstasy.3 However, there
are geographical and population variances in GHB use.
[For instance, in New Orleans, there have been reports of
GHB use among secondary school and college students,
whereas, in other areas, it is reputed to be widely accessible
at gay male party venues.7]
Bodybuilders have reported that they use GHB because it
stimulates the release of growth hormones. People who are
alcohol dependent may use it to try to eliminate alcohol
cravings, even though there is no medical approval for this
use in the United States.
Despite the belief of some users that GHB is a safe body
building or sleep aid, or a party drug that poses no risk for
addiction or overdose, the effects of GHB can be tragic.
The only legitimate use of GHB in the United States is for
the treatment of cataplexy, a symptom of the sleep disorder
narcolepsy in which muscles lose strength. The U.S. Food
and Drug Administration approved GHB, under the brand
name Xyrem, on July 17, 2002, but mandated some of the
most severe restrictions ever imposed on a medicine.8
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Why is GHB so dangerous?
GHB, usually in combination with alcohol, was linked to
more than 60 deaths from January 1992 to May 2001.
Almost 60 percent of these deaths were people between
ages 20 and 29. However, the number of GHB-related
deaths may be underestimated because GHB does not
remain in the body long and is usually not tested for at
autopsy.1 GHB may be missed by many conventional 
urine drug screens.4
The effects of GHB vary each time a person takes it, and it
affects each person differently. 4 A small increase in dose
can increase the drugs sedative effects to a lethal level.
High doses of GHB may overwhelm the bodys ability to
eliminate the drug; therefore, the effects are greater and
last longer than expected.1
The adverse effects of GHB include vomiting, seizure-like
activity, loss of consciousness, respiratory arrest, coma,
and death. GHB often is produced in clandestine laboratories;
therefore, the purity and strength of doses vary. This 
situation makes it difficult for emergency personnel to
obtain useful information on the amount of GHB that a
person took.

How is GHB used in date rape?
GHB has been slipped into unsuspecting victims drinks.
GHBs taste can be masked by adding it to a flavored 
beverage. Because it is hard to detect GHB in a beverage,
and because only small amounts are needed to achieve the
desired effect, GHB has been used to facilitate rapes.
Victims given GHB become unconscious and cannot
defend themselves from these sexual assaults. They cannot
serve as witnesses in court because amnesia is another
effect of consuming GHB.4
GHB has been implicated in deaths as well. For instance,
in January 1999, 15-year-old Samantha Reid was
Why has there been so much media
attention focused on GHB lately?

During the past decade, the use of GHB and GBL has
increased. According to the Substance Abuse and Mental
Health Services Administrations (SAMHSAs) Drug
Abuse Warning Network (DAWN), the number of
emergency department (ED) visits in which GHB is
mentioned, including those in which GBL is mentioned,
increased from 56 in 1994 to 4,969 in 2000.9 In 2000,
GHBagain, including GBLranked 34th among 50
most mentioned drugs in ED drug-related episodes.

2

-----------------------------------------------
November 2002, GHB: A Club Drug To Watch

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ADVISORY
Substance Abuse Treatment

scooped (the street term for slipping GHB into 
someones drink). Reid lost consciousness and died the
next day.5 The teenage boys who scooped her drink were
sentenced to prison for manslaughter.10 Hillary J. Farias was
raped after being slipped GHB. On February 18, 2000, the
Hillary J. Farias and Samantha Reid Date-Rape Drug
Prohibition Act of 2000 became law, making GHB a
Schedule 1 drug.
What can treatment providers
do to help?

Providers should learn all they can about GHBincluding
regional trends related to its usebecause client education
about the dangers of GHB is critical, particularly as
reports of its euphoric effects may cause an increase in
experimentation.
Substance abuse treatment professionals should assess a
clients lifestyle and drug use habits before the client expe
riences adverse effects and requires medical intervention. 
If a client is known to be experimenting with GHB or
other club drugs, treatment providers should alert him or
her to the adverse effects and provide emergency medical
information from a poison control center or appropriate
healthcare facility. Some experts suggest that clients with 
a history of bodybuilding be assessed for GHB abuse
because this drug is commonly used in this patient popula 
tion.4 Providers should also warn clients that misinformation
about GHB is available on the Internet. Many people who
take the drug do not know of its dangers. For instance,
only 9 GHB users in a study of 42 regular GHB users were
aware that it could produce a withdrawal reaction.12 (See
the box on the back page for more information about 
regular GHB users.)
Knowing when patients need medical attention and 
referring them to appropriate care are key. n

Notes
1Whitten, L. Conference Highlights Increasing GHB Abuse. NIDA Notes.
Bethesda, MD: National Institute on Drug Abuse. Retrieved April 5, 2002, from the
World Wide Web, www.drugabuse.gov/NIDA_Notes/NNVol16N2/Conference.html.
2Office of Applied Studies. Club Drugs. The DAWN Report. Rockville, MD:
Substance Abuse and Mental Health Services Administration, 10 pp., December
2000.
3Executive Office of the President, Office of National Drug Control Policy. Pulse
Check: Trends in Drug Abuse. ONDCP Pub. No. (NCJ) 191248. Washington,
DC: Office of National Drug Control Policy, pp. 7588, November 2001.
Do people on GHB develop 
dependence and experience 
withdrawal symptoms?

Severe GHB dependence was found to follow daily use 
of varying amounts of GHB over a period ranging from 
2 months to 3 years according to the findings in a retro-
spective study of eight patients with prolonged withdrawal
symptoms after discontinuing chronic use of GHB.11
Researchers found that withdrawal symptoms started
between 1 and 6 hours after the last dose and lasted
between 5 and 15 days. One person died from cardiac
complications on the 13th day in the hospital. Reported
withdrawal symptoms included:
 Psychosis and severe agitation requiring self-protection
procedures and sedation
 Mild tachycardia (increased heart rate) and hypertension
 Neurologic effects, including prolonged delirium
 Hallucinations
 Diaphoresis (profuse sweating), nausea, and vomiting.

What are the symptoms of a GHB
overdose?

Symptoms of GHB overdose include nausea, bradycardia
(slow heart rate), and a decreased level of consciousness.
Alcohol, opioids, barbiturates, and benzodiazepines 
potentiate the effects of GHB.12 In GHB overdoses, it is
imperative to keep patients airways open, with assisted
ventilation if necessary, and provide supportive care. GHB
use should be considered when any patient presents with a
coma of unknown origin.4

3

-----------------------------------------------
November 2002, Volume 2, Issue 1

Substance Abuse Treatment

Survey of 42 Self-Reporting Regular GHB Users12

Positive Effects of GHB UseEuphoria, increased sex drive, and tranquility.
Adverse EffectsSweating and loss of consciousness (reported by 69 percent),
nausea, auditory and visual hallucinations, headaches, vomiting, exhaustion, 
sluggishness, amnesia, confusion, and clumsiness.
Rate of Use18 participants used GHB 2 or 3 times daily, 12 participants 
4 or more times daily, and 12 participants once daily.
Positive effects of GHB use, as compared with adverse 
experiences, were emphasized by participants. However, 
family members reported a change in personality, including 
increased aggression, irritability, and memory problems.
Participants who used GHB with other substances reported 
more severe adverse events than those who used GHB alone. n

4Teter, C.J., and Guthrie, S.K. A Comprehensive Review of MDMA and
GHB: Two Common Club Drugs. Pharmacotherapy 21(12):14861513, 2001.
5Cannon, A. Sex, Drugs, and Common Death. U.S. News and World
Report, May 24, 1999.
6National Drug Intelligence Center. Drugs and the InternetAn
Overview of the Threat to Americas Youth. Retrieved April 30, 2002,
from the World Wide Web, www.usdoj.gov/ndic/pubs/682.
7Community Epidemiology Work Group. Epidemiologic Trends in Drug
Abuse, Advanced Report. Bethesda, MD. National Institute on Drug
Abuse, June 1999. Retrieved September 13, 2002, from the World Wide
Web, 165.112.78.61/CEWG/AdvancedRep/699ADV/699adv.html.
8Center for Drug Evaluation. FDA Drug Approvals List. U.S. Food and
Drug Administration. Retrieved July 31, 2002, from the World Wide Web,
www.fda.gov/cder/whatsnew-date.htm.
9Office of Applied Studies. Emergency Department Trends From the Drug
Abuse Warning Network, Preliminary Estimates JanuaryJune 2001 With
Revised Estimates 19942000. DAWN Series D-20. DHHS Pub. No.
(SMA) 023634. Rockville, MD: Substance Abuse and Mental Health
Services Administration, p. 104, 2002. 
10Associated Press. Three Convicted in Date-Rape Drug Trial. March
14, 2000. Retrieved September 13, 2002, from the World Wide Web, 
abcnews.go.com/sections/us/DailyNews/daterape000314.html.
11Dyer, J.E.; Roth, B.; and Hyma, B.A. Gamma-hydroxybutyrate
Withdrawal Syndrome. Annals of Emergency Medicine 37(2):14753, 2001.
12Miotto, K.; Darakjian, J.; Basch, J.; Murray, S.; Zogg, J.; and Rawson,
R. Gamma-hydroxybutyric Acid: Patterns of Use, Effects, and
Withdrawal. American Journal on Addictions 10(3):23241, 2001.
ADVISORY
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Notes (continued)
Substance Abuse Treatment Advisory
Substance Abuse Treatment Advisorypublished on an as-needed basis
for treatment providerswas produced by Johnson, Bassin & Shaw, Inc.,
under contract 270-99-7072, for the Center for Substance Abuse
Treatment (CSAT), of the Substance Abuse and Mental Health Services
Administration (SAMHSA), U.S. Department of Health and Human
Services (HHS). Edwin M. Craft, Dr.P.H., LCPC, serves as the
SAMHSA editor of the publication. The content of this publication does
not necessarily reflect the views or policies of SAMHSA or HHS. For
further information or to request information about  Substance Abuse
Treatment Advisory, please contact Dr. Craft at ecraft@samhsa.gov.
Public Domain Notice: All material appearing in this report is in the
public domain and may be reproduced or copied without permission;
citation of the source is appreciated. However, this publication may not
be reproduced or distributed for a fee without the specific, written
authorization of the Office of Communications, SAMHSA, HHS.
Electronic Access and Copies of Publication: This publication can be
accessed electronically through the Internet at www.samhsa.gov/
centers/csat2002/csat_frame.html. Additional free print copies can be
ordered from SAMHSAs National Clearinghouse for Alcohol and Drug
Information at 1-800-729-6686.
Recommended Citation: Center for Substance Abuse Treatment. GHB: 
A Club Drug To Watch. Substance Abuse Treatment Advisory. Volume 2,
Issue 1, November 2002.

National Clearinghouse for Alcohol and Drug Information
Substance Abuse and Mental Health Services Administration
U.S. Department of Health and Human Services
7079 Oakland Mills Road
Columbia, MD  21046
PRSRT STD
U.S. POSTAGE
    PAID
COLUMBIA, MD
PERMIT NO. 259

DHHS Publication No. (SMA) 03-3766
NCADI Publication No. MS915
Printed 2002